Thursday, March 17, 2011

The atherogenic lipid phenotype (ALP)

---is a major cause of residual cardiovascular risk after statin treatment “to goal.” Treatment options are discussed in this review:

Large outcome trials designed to assess the value of combining statins with other agents to target HDL cholesterol and non-HDL cholesterol will not be completed for a few years, but there is ample evidence for the clinician to consider combination therapy. The choices for therapies to supplement statins include niacin, fibrates, and omega-3 fatty acids.

No comments: